纖溶酶原激活物抑制劑
The high-phenol group also experienced a greater drop in the activity of another clot promoter, plasminogen activator inhibitor-1.
高酚早餐組另一血栓促進因子——纖維蛋白溶酶原活化抑制因子-1的活性也呈現顯著降低。
Objective To study the relationship of plasminogen activator inhibitor type 1(PAI 1) to platelet activity in elderly patients with unstable angina pectoris(UAP).
目的探讨老年不穩定型心絞痛（UAP）與纖溶酶原激活物抑制劑1型（PAI 1）及血小闆活化功能的臨床意義。
Objective To study the expression of plasminogen activator inhibitor-1(PAI-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis (AS).
目的通過對動脈粥樣硬化（AS）兔血清和粥樣硬化斑塊中纖溶酶原激活物抑制物-1（PAI-1）表達的研究，探讨PAI-1在AS中的作用。
Objective:To examine whether VLDL or LDL can stimulate the secretion of plasminogen activator inhibitor type 1 (PAI-1) in hepatic cells.
目的：觀察極低密度脂蛋白（VL DL）與低密度脂蛋白（L DL）是否能刺激肝細胞纖溶酶原激活物抑制物- 1（PAI- 1）的分泌。
Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.
纖溶酶原激活物抑制物1（PAI-1）是血漿纖維蛋白溶解系統的重要組成物之一，對維持血漿纖溶系統的穩定起重要作用。
Objective: To investigate the protein expression of plasminogen activator inhibitor(PAI 1) in renal tissue of hypercholesterolemia rats and the effect of Irbesartan.
目的：①了解纖溶酶原激活物抑制劑1（PAI1）在高膽固醇大鼠血及腎皮質的表達及其與腎髒損害的關系；
Plasminogen activator inhibitor-1(PAI-1)is the main regulator of the fibrinolytic system.
血漿纖溶酶原激活物抑制劑（PAI）-1是纖溶系統的主要調控因子。
Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).
目的研究前炎症細胞因子對人胸膜間皮細胞（HPMC）釋放纖溶酶原激活物抑制劑（PAI1）的誘導效應。
Objective To investigate the plasma tissue-type plasminogen activator(t-PA) and plasminogen activator inhibitor(PAI) in coronary heart disease patients with angina pectoris and its probable mechanism.
目的探讨冠心病心絞痛病人血漿組織型纖溶酶原激活物（tPA）及其抑制物（PAI）活性的變化及其可能機制。
AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).
目的：觀察銀杏葉提取物對2型糖尿病病人纖溶酶原激活物抑制物1（PAI1）及凝血烷B2（TXB2 ）的影響。
Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.
方法：檢測33例糖尿病腎病患者及30例健康體檢對照組血漿纖溶酶原激活物抑制物-1（PAI-1），觀察檢測結果。
Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
結論：糖尿病腎病患者存在血漿纖溶酶原激活物及其抑制物系統失衡。
The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.
用酶聯免疫吸附法檢測血漿血管性假性血友病因子、凝血酶調節蛋白、纖溶酶原激活物抑制物1水平。
Objective To study the effects of transient cerebral ischemic reperfusion(IR) and flunarizine on the expression of plasminogen activator inhibitor-1(PAI-1) protein in brain tissue of gerbils.
目的研究沙鼠腦缺血再灌注後腦内1型纖溶酶原激活物抑制劑（PAI-1）蛋白表達變化，以及西比靈幹預的影響。
Objective To explore the relationship between plasminogen activator inhibitor type-1 (PAI-1)and its biological behaviour of hepatocellular carcinoma (HCC).
目的研究纖溶酶原激活物抑制劑（PAI-1）與肝癌臨床生物學特性的關系。
Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.
目的探讨纖溶酶原激活物抑制物- 1（PAI-1）啟動子區基因多态性與腦卒中的關系。
ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.
為探讨纖溶酶原激活物抑制因子1（PAI1）在腎損傷後纖維化中的作用和意義，揭示其發病的分子病理機制。
Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纖溶酶原激活物抑制劑1（PAI-1）是一種單鍊糖蛋白，起抑制纖溶活性的作用。
Objective To monitor the dynamic changes of tissue type plasminogen activator(t-PA) and plasminogen activator inhibitor-I(PAI-I) activity after and before PTCA in patients with ACS.
目的觀察急性冠脈綜合征（ACS）患者冠脈成形術（PTCA）前後血漿組織型纖溶酶原激活物（t-PA）及纖溶酶原激活抑制劑（PAI-I）的動态變化。
Objective To study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).
目的研究纖溶酶原激活物抑制劑（PAI1）與肝細胞癌（HCC）生物學特性的關系。
Aim:To explore the relationship between genetic polymorphisms of type I plasminogen activator inhibitor (PAI 1) and ischemic stroke.
目的：探讨血漿I型纖溶酶原激活物抑制劑基因多态性與中國人缺血性腦卒中之間的關系。
Plasma endothelin 1(ET 1), tissue type plasminogen activator(t PA) and plasminogen activator inhibitor 1(PAI 1) were stu***d before and after ECP.
觀察ECP前後内皮源性血管活性物質内皮素-1（ET-1）、組織型纖溶酶原激活物（t-PA）及其抑制劑（PAI-1）的變化。
Objective To study the effects of atorvastatin cholesterol-lowering therapy on vascular endothelial function and plasminogen activator inhibitor-1 in acute coronary syndromes.
目的：探讨急性冠脈綜合征患者應用阿托伐他汀調脂治療後對血管内皮舒張功能、血漿纖溶酶原激活物抑制物1及血管内皮素1的影響。
Plasminogen activator inhibitor-1(PAI-1) is a single-chain glycoprotein secreted by many kinds of cells, which participates in many physiological process.
血漿纖溶酶原激活劑抑制物1（PAI-1）是由多種細胞分泌的糖化蛋白，在體内參與多種生理過程。
Objective: To explore the effect of thrombin on cell proliferation and plasminogen activator inhibitor Type 1(PAI 1) expression in human embryonic glomerular mesangial cells.
目的 ：探讨凝血酶對人胚胎腎系膜細胞增殖和纖溶酶原激活物抑制物1 （PAI1 ）表達的影響。
The researchers also found that plasminogen activator inhibitor type 2 (PAI2), a serine-protease inhibitor, inhibited proteolytic truncation of annexin-1 in macrophages infected with M. tuberculosis.
研究者還發現2型纖維蛋白溶酶原激活因子抑制物（PAI2）（一種絲氨酸蛋白酶抑制物）抑制結核杆菌感染的巨噬細胞内的膜聯蛋白-1的蛋白水解作用。
纖溶酶原激活物抑制劑（Plasminogen Activator Inhibitor, PAI） 是人體内一類重要的絲氨酸蛋白酶抑制劑（Serpin），其主要功能是特異性抑制纖溶酶原激活物（如組織型纖溶酶原激活物t-PA和尿激酶型纖溶酶原激活物u-PA）的活性。纖溶系統負責溶解血栓（纖維蛋白凝塊），而PAI通過抑制纖溶酶原激活物，間接抑制纖溶酶的形成，從而負向調控纖溶過程，維持凝血與纖溶系統的動态平衡。
纖溶酶原激活物抑制劑（PAI），特别是PAI-1，是纖溶系統的主要負調控因子，通過抑制t-PA和u-PA的活性來限制纖溶酶生成和纖維蛋白溶解。它在維持正常止血、防止過度出血中不可或缺，但其水平異常升高（常見于代謝性疾病和炎症狀态）是血栓形成的重要機制。此外，PAI在組織纖維化和腫瘤生物學中也扮演着複雜角色。理解PAI的功能對于認識血栓性疾病、纖維化疾病和腫瘤轉移的病理生理學至關重要。
注： 為提供最權威準确的信息，本文内容嚴格依據醫學教科書、權威綜述及高質量臨床研究撰寫。由于當前檢索環境限制，未能實時獲取并标注具體線上文獻鍊接。建議讀者在需要驗證或深入探究時，查閱如Blood、Arteriosclerosis, Thrombosis, and Vascular Biology、Journal of Thrombosis and Haemostasis等專業期刊的最新文獻，或參考UpToDate、Medscape等循證醫學資源平台。
Plasminogen Activator Inhibitor（PAI） 是纖溶系統中的關鍵調節蛋白，主要用于抑制纖溶酶原激活物（如tPA、uPA），從而調控纖維蛋白溶解過程。以下是詳細解釋：
PAI屬于絲氨酸蛋白酶抑制劑（serpin）家族，通過結合并中和纖溶酶原激活物的活性，阻止其将纖溶酶原轉化為纖溶酶。這種抑制作用在維持血液凝固和纖溶系統的動态平衡中至關重要。
PAI-1的檢測常用于評估血栓傾向或纖溶功能異常。其多克隆抗體在生物學研究中用于蛋白定位、定量及機制探索。
如需進一步了解PAI的臨床檢測方法或疾病相關性，可參考相關生物醫學數據庫或研究文獻。
paralyzecreedChristianitymurmursRosasubjectingswattingtransgressionstrovetubersdemocratic revolutiondraft tubefull fledgedhave patienceout of syncpatent pendingsad facestatistical informationYour Majestybismitecascarilladieciousdinoprostdogmeatdroshkyepicutishypouricuriaiminelindanemaltcrusher